Alkaline Phosphatase Level Increase with Initiation of Hormone Therapy for Prostate Cancer Portends Poor Prognosis with Rapid Progression to Bone Metastases: A Case Report and Review of the Literature

2006 ◽  
Vol 4 (4) ◽  
pp. 293-295 ◽  
Author(s):  
Michael W. Brown ◽  
Anurag K. Singh
Keyword(s):  
Prostate Cancer ◽  
Alkaline Phosphatase ◽  
Case Report ◽  
Bone Metastases ◽  
Hormone Therapy ◽  
Poor Prognosis ◽  
Alkaline Phosphatase Level ◽  
Rapid Progression ◽  
Review Of The Literature ◽  
Level Increase

Malignant Rhabdoid Tumor of the Kidney in an Adult: A Case Report and Review of the Literature

2003 ◽  
Vol 127 (9) ◽  
pp. e371-e373 ◽  
Author(s):  
Hong Qi Peng ◽  
Albert E. Stanek ◽  
Saul Teichberg ◽  
Barry Shepard ◽  
Ellen Kahn
Keyword(s):  
Case Report ◽  
Aggressive Behavior ◽  
Poor Prognosis ◽  
Renal Tumor ◽  
Adult Population ◽  
Rhabdoid Tumor ◽  
Malignant Rhabdoid Tumor ◽  
Review Of The Literature ◽  
Electron Microscopic ◽  
Rhabdoid Tumors

Abstract Malignant rhabdoid tumor of the kidney is an uncommon renal tumor in children. The tumor has aggressive behavior and a poor prognosis and is extremely rare in adults; only 3 cases of renal rhabdoid tumors have been reported in adults. We describe here the microscopic, immunohistochemical, and electron microscopic characteristics of another case in a 38-year-old woman. This case reinforces the importance of recognizing this entity in the adult population.

scholarly journals Brucellosis mimicking prostate cancer: Case report and review of the literature

2017 ◽  
Author(s):  
Lütfi Canat ◽  
Akif Erbin ◽  
Hasan Tahsin Gözdaş ◽  
Hasan Anıl Atalay
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Cancer Case ◽  
Prostate Cancer Case ◽  
Review Of The Literature

Circulating chromogranin A as a marker for poor-prognosis hormone refractory prostate cancer without neuroendocrine features: Prospective analyses of a cohort of patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e16130-e16130
Author(s):  
P. Maroto-Rey ◽  
N. Sala ◽  
J. Mora ◽  
H. Villavicencio ◽  
S. Esquena ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Alkaline Phosphatase ◽  
Gleason Score ◽  
Chromogranin A ◽  
Poor Prognosis ◽  
Serum Alkaline Phosphatase ◽  
Refractory Disease ◽  
Initial Biopsy ◽  
Double Time ◽  
Hormone Refractory

e16130 Background: Some patients may develop hormone refractory prostate (HRPC) cancer with neuroendocrine features, although they were not recognizable in the initial biopsy. Serum chromogranin is a marker for tumors with neuroendrocrine differentiation. Purpose: To analyze if serum levels of chromogranin A may identify poor prognosis HRPC patients in patients without neuroendocrine features in the initial biopsy. Methods: Circulating chromogranin A was prospectively analyzed in 34 patients when they were diagnosed under the standard criteria of HRPC. A patient was considered to have higher than normal levels of serum chromogranin if levels were above 100 ug/L. Patients were also assessed for serum PSA, enolase, serum alkaline phosphatase, albumin, and hemoglobin. Results were correlated with clinical prognostic factors as ECOG, PSA double time and Gleason score. We analyzed the time to hormone-refractory disease since diagnosis, and overall survival, as well as pattern of relapse (visceral vs. nonvisceral disease). Results: Median age was 63 (49–85). Median PSA was 33 (0.04–1455). At baseline, 16 patients were chromogranin-negative (46%), and 18 patients were chromogranin-positive (54). Chromogranin A did not correlate with either enolase or PSA. Patients with positive (>100 ug/L) had stadistically significant lower levels of hemoglobine (13.8 vs 12.3), and a trend to have more visceral disease vs locoregional diasease or bone metastases, a lower albumine level (39.85 vs 45.05), higher alkaline phosphatase (221 vs 111), and LDH (1,914.5 vs 415). In this group of patients, we did not find differences in PSA double time, time to hormone-refractory disease or Gleason score. Conclusions: The analysis of this cohort of patients suggests that serum chromogranine A correlates with other known adverse prognosis factors of survival in prostate cancer patients. No significant financial relationships to disclose.

Prostate Cancer with Testicular Metastasis: A Case Report and Mini-Review of the Literature

2004 ◽  
Vol 71 (4) ◽  
pp. 300-301
Author(s):  
M. Fiorello ◽  
V. Fulcoli ◽  
D. Lavelli ◽  
G. Bortuzzo
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Review Of The Literature ◽  
Testicular Metastasis

Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4642-4642 ◽  
Author(s):  
Karim Fizazi ◽  
Christophe Massard ◽  
Matthew Raymond Smith ◽  
Michael E. Rader ◽  
Janet Elizabeth Brown ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Alkaline Phosphatase ◽  
Bone Metastases ◽  
Clin Oncol ◽  
Performance Status ◽  
Prognostic Significance ◽  
Phase Iii ◽  
Prognostic Models ◽  
Selection Strategies ◽  
Baseline Covariates

4642 Background: Prognostic models of OS in men with metastatic castrate-resistant prostate cancer (M+CRPC), have been limited. Here we present an analysis of baseline covariates associated with OS from an international phase 3 study that demonstrated superiority of denosumab over zoledronic acid for prevention of skeletal-related events (SRE) in this population (Fizazi et al., Lancet 2011;377:813-822). Methods: Patients had confirmed bone metastases (BM) from CRPC (a rising PSA despite castrate testosterone levels) and no prior bone anti-resorptive therapy. Proportional hazards modeling with various selection strategies was used to assess the prognostic significance of baseline covariates in multivariate analyses. Study-specified factors (previous SRE [Y vs N], PSA level [<10 vs ≥10 ng /mL]) and additional variables (Cook et al., Clin Cancer Res 2006;12:3361-3367; Halabi et al., J Clin Oncol 2003;21:1232-1237; Halabi et al., J Clin Oncol 2008;26:2544-2549) were explored. As no difference in OS was observed between treatment arms, analyses were performed using the pooled overall patient population. Results: Analyses included all randomized subjects with available baseline covariate data (n=1745). At the primary analysis date (median study duration 12.2 months), OS was 51%. Various selection strategies produced consistent results. In multivariate analysis, bone-specific alkaline phosphatase (BAP) ≥146 μg/L (p<0.0001) and corrected urinary N-telopeptide (uNTx) >50 nmol/mmol (p=0.0008) were associated with shorter OS, as were prior SRE (p=0.0002), PSA ≥10 ng /mL (p<0.0001), visceral metastases (p=0.0002), greater time from either diagnosis to first BM or first BM to randomization (p<0.0001 for both), ECOG performance status 2 vs. 0/1 (p=0.017), BPI-SF pain score >4 (p<0.0001), age (p=0.008), alkaline phosphatase >143 U/L (p<0.0001), and hemoglobin ≤128 g/L (p<0.0001). Conclusions: Besides known factors previously associated with OS in men with CRPC (Halabi et al., 2003), we show that bone-associated covariates (pain, prior SRE, BAP, and uNTx) are also important and independent prognostic factors for OS.

scholarly journals Sarcomatous Carcinoma of the Orbit: A Case Report and Review of the Literature

2015 ◽  
Vol 6 (2) ◽  
pp. 180-185
Author(s):  
Ninan Mathew ◽  
Mathen Mathew ◽  
Jon Farrah
Keyword(s):  
Case Report ◽  
Poor Prognosis ◽  
Advanced Disease ◽  
English Literature ◽  
Treatment Options ◽  
Malignant Cells ◽  
Review Of The Literature ◽  
Immunological Markers ◽  
Rare Tumours ◽  
The Right

Sarcomatous carcinomas (SCs) are rare tumours that contain malignant cells with epithelial and mesenchymal characteristics. SC rarely presents in the head and neck, and occurs even less often in the orbit. Only 8 cases of SCs located in the orbit or affecting the globe function have been described in the English literature. Here, we report a case of SC affecting the right orbit. SC is associated with a poor prognosis and advanced disease at presentation. Diagnosis is difficult, as histology often fails to definitively identify SC, necessitating a wide panel of molecular/immunological markers. Treatment options are generally aggressive but risky, and frequently yield poor results. Due to the rarity of SC, there has been little focus on the development of improved treatment options.

scholarly journals Case report and review of the literature: Rectal linitis plastica secondary to the lipoid cell variant of transitional cell carcinoma of the urinary bladder

2012 ◽  
Vol 6 (6) ◽  
pp. 431 ◽  
Author(s):  
Victor A. McPherson ◽  
Michael Ott ◽  
Edward J. Tweedie ◽  
Jonathan Izawa
Keyword(s):  
Case Report ◽  
Poor Prognosis ◽  
Transitional Cell ◽  
Linitis Plastica ◽  
Lower Gastrointestinal Tract ◽  
Disease Entity ◽  
Review Of The Literature ◽  
Unique Case ◽  
Carcinoma Of The Bladder ◽  
Cell Variant

The overall 5-year survival of patients with urothelial carcinoma of the bladder (UC) is about 78%; however, there are some rare subtypes. One of these is the lipoid cell subtype, which bears a very poor prognosis. Another rare disease entity with a poor prognosis is metastasis to the lower gastrointestinal tract in the form of secondary linitis plastica of the rectum. We describe an extremely rare and unique case of rectal linitis plastica secondary to the rare lipoid cell variant of UC.

scholarly journals Sinonasal Lymphoma Presenting as a Probable Sanctuary Site for Relapsed B Acute Lymphoblastic Leukaemia: A Case Report and Review of the Literature

2015 ◽  
Vol 2015 ◽  
pp. 1-5
Author(s):  
W. Y. Lim ◽  
R. Care ◽  
M. Lau ◽  
S. Chiruka ◽  
P. J. D. Dawes
Keyword(s):  
Case Report ◽  
Acute Lymphoblastic Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Nasal Septum ◽  
Poor Prognosis ◽  
Lymphoblastic Lymphoma ◽  
Late Relapse ◽  
Review Of The Literature ◽  
Unique Case ◽  
Non Hodgkin Lymphoma

Sinonasal lymphoma is a non-Hodgkin lymphoma (NHL) representing 1.5% of all lymphomas. It presents as an unremitting ulceration with progressive destruction of midline sinonasal and surrounding structures. Poor prognosis warrants early treatment although diagnosis is challenging and frequently delayed. It is usually primary in origin and to our knowledge the sinonasal region has never been reported as a sanctuary site in leukaemia/lymphoma relapse. We present a unique case of B-cell ALL (acute lymphoblastic leukaemia) with late relapse to the nasal septum as a sinonasal lymphoblastic lymphoma and with genetic support for this as a sanctuary site.

Sign in / Sign up

Export Citation Format

Share Document